Prevalence of and risk factors for adverse events in Alzheimer's patients receiving anti-dementia drugs in at-home care.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Home Care Services*; Alzheimer Disease/*drug therapy ; Inappropriate Prescribing/*statistics & numerical data ; Nootropic Agents/*adverse effects; Aged ; Aged, 80 and over ; Female ; Humans ; Japan ; Male ; Nootropic Agents/therapeutic use ; Pharmacists ; Polypharmacy ; Prevalence ; Retrospective Studies ; Risk Factors ; Surveys and Questionnaires
    • Abstract:
      Objective: The objective of this study was to clarify the types and prevalence of, and the risk factors for, the adverse events that occur in patients receiving anti-dementia drugs.
      Methods: A questionnaire survey was conducted. The respondents were pharmacists who were dispensing anti-dementia drugs. The pharmacists responded to questions about patients who were receiving anti-dementia drugs delivered to them at home by the pharmacists. The survey questions included questions about whether or not the patients experienced adverse reactions to the drugs, about the patients' background characteristics, about the numbers of drugs the patients were taking when the pharmacists first visited the patients at home, and about the pharmacists' assessments of the appropriateness of the use of the anti-dementia drugs.
      Results: Data were collected on 3712 patients from 1673 pharmacies in a nationwide survey. Anti-dementia drugs had been prescribed to 863 of these patients; and 801 (92.8%) of these 863 patients were 75 years of age or older, and. confirmed adverse events occurred in 170 (21%) of these 863 patients. The most common adverse event was excitation/anxiety, at 45.1%. A multivariate analysis found that polypharmacy (10 or more types of drugs per day) (P = 0.030), inappropriate use (P = 0.002), and irregular medication use (P = 0.034) were risk factors.
      Interpretation: In order to avoid adverse events when using anti-dementia drugs, doctors and pharmacists should carefully examine the prescribing of multiple medications, assess the applicability of the use of anti-dementia drugs, and investigate how to best manage patients' drug use.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      Psychiatry (Edgmont). 2008 Nov;5(11):27-36. (PMID: 19724715)
      Curr Med Res Opin. 2005 May;21(5):723-32. (PMID: 15969871)
      Arch Intern Med. 2009 May 11;169(9):867-73. (PMID: 19433698)
      Curr Ther Res Clin Exp. 2003 Apr;64(4):216-35. (PMID: 24944370)
      Alzheimer Dis Assoc Disord. 2011 Oct-Dec;25(4):333-40. (PMID: 21399485)
      Lancet Public Health. 2017 Mar;2(3):e149-e156. (PMID: 29253388)
      Int J Toxicol. 2001 May-Jun;20(3):149-52. (PMID: 11488556)
      Drugs Aging. 2017 Apr;34(4):303-310. (PMID: 28258538)
      Drug Saf. 2017 Aug;40(8):679-692. (PMID: 28439716)
      Lancet Neurol. 2006 Feb;5(2):103. (PMID: 16426980)
      BMJ. 2006 Jul 22;333(7560):165. (PMID: 16858027)
      Int J Epidemiol. 2018 Jun 1;47(3):709-719. (PMID: 29444280)
      N Engl J Med. 2003 Apr 3;348(14):1333-41. (PMID: 12672860)
      Psychiatr Danub. 2009 Mar;21(1):108-13. (PMID: 19270633)
      Lancet Neurol. 2019 Jan;18(1):88-106. (PMID: 30497964)
      J Control Release. 2012 Jul 20;161(2):389-98. (PMID: 22289435)
      Alzheimers Res Ther. 2015 Mar 26;7(1):34. (PMID: 25815064)
      Int J Geriatr Psychiatry. 2018 May 20;:. (PMID: 29781202)
      Neurodegener Dis Manag. 2018 Aug;8(4):257-266. (PMID: 30040019)
      Drugs Aging. 2014 Oct;31(10):769-76. (PMID: 25200414)
      Ir J Med Sci. 1999 Oct-Dec;168(4):257-61. (PMID: 10624366)
      J Alzheimers Dis. 2015;49(1):211-20. (PMID: 26444790)
      Seishin Shinkeigaku Zasshi. 2016;118(2):77-82. (PMID: 30629352)
      J Am Geriatr Soc. 2017 Oct;65(10):2213-2219. (PMID: 28832937)
      J Am Geriatr Soc. 2018 Jan;66(1):170-178. (PMID: 29131306)
      BMJ. 2006 Jan 28;332(7535):195. (PMID: 16439382)
      Nat Med. 2006 Jul;12(7):780-4. (PMID: 16829947)
      Curr Med Res Opin. 2007 Aug;23(8):1829-35. (PMID: 17599785)
      Am Fam Physician. 2011 Jun 15;83(12):1403-12. (PMID: 21671540)
      BMJ. 1998 Jul 11;317(7151):119-20. (PMID: 9657787)
      Alzheimers Res Ther. 2015 Sep 26;7(1):60. (PMID: 26407550)
    • Accession Number:
      0 (Nootropic Agents)
    • Publication Date:
      Date Created: 20200407 Date Completed: 20200714 Latest Revision: 20200714
    • Publication Date:
      20231215
    • Accession Number:
      PMC7135264
    • Accession Number:
      10.1371/journal.pone.0231226
    • Accession Number:
      32251456